Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection

Science Translational Medicine

Volumn 9, Issue 377, 2017, Pages

  Takata, Hiroshi ^a,b   Buranapraditkun, Supranee ^a,b,c   Kessing, Cari ^d   Fletcher, James L K ^e   Muir, Roshell ^f   Tardif, Virginie ^f   Cartwright, Pearline ^g   Vandergeeten, Claire ^h   Bakeman, Wendy ^h   Nichols, Carmen N ^h   Pinyakorn, Suteeraporn ^a,b   Hansasuta, Pokrath ^c,i   Kroon, Eugene ^e   Chalermchai, Thep ^e   O'Connell, Robert ^j   Kim, Jerome ^k   Phanuphak, Nittaya ^e   Robb, Merlin L ^a,b   Michael, Nelson L ^a   Chomont, Nicolas ^l   Haddad, Elias K ^f   Ananworanich, Jintanat ^a,b,e   Trautmann, Lydie ^a,b   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Vaccine and Gene Therapy Institute of Florida   (United States)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^k International Vaccine Institute   (South Korea)

^l CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; TUMOR NECROSIS FACTOR; VIRUS DNA; CYTOKINE;

ADULT; ANTIRETROVIRAL THERAPY; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FATE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; VIREMIA; VIRUS CARRIER; VIRUS LOAD; ACUTE DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE CARRIER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; METABOLISM; PATHOLOGY; SURVIVAL ANALYSIS; VIROLOGY;

ACUTE DISEASE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DISEASE RESERVOIRS; FEMALE; HIV INFECTIONS; HUMANS; MALE; SURVIVAL ANALYSIS; VIRAL LOAD; VIREMIA;

EID: 85013399115     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag1809     Document Type: Article

References (59)

1. A. J. McMichael, S. L. Rowland-Jones, Cellular immune responses to HIV. Nature 410, 980-987 (2001).
2. ∗5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl. Acad. Sci. U.S.A. 97, 2709-2714 (2000).
3. H. Chen, Z. M. Ndhlovu, D. Liu, L. C. Porter, J. W. Fang, S. Darko, M. A. Brockman, T. Miura, Z. L. Brumme, A. Schneidewind, A. Piechocka-Trocha, K. T. Cesa, J. Sela, T. D. Cung, I. Toth, F. Pereyra, X. G. Yu, D. C. Douek, D. E. Kaufmann, T. M. Allen, B. D. Walker, TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nature 13, 691-700 (2012).
4. + T cells control AIDS virus replication. Nature 491, 129-133 (2012).
5. R. A. Koup, J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, D. D. Ho, Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
6. + T cells with a predominant Vb usage during the primary immune response to HIV. Nature 370, 463-467 (1994).
7. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
8. + T cells in acute HIV-1 infection inhibit transmitted/founder virus replication. J. Virol. 86, 6835-6846 (2012).
9. C. L. Day, D. E. Kaufmann, P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, Z. Mncube, J. Duraiswamy, B. Zhu, Q. Eichbaum, M. Altfeld, E. J. Wherry, H. M. Coovadia, P. J. Goulder, P. Klenerman, R. Ahmed, G. J. Freeman, B. D. Walker, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
10. + T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198-1202 (2006).
11. R. B. Jones, L. C. Ndhlovu, J. D. Barbour, P. M. Sheth, A. R. Jha, B. R. Long, J. C. Wong, M. Satkunarajah, M. Schweneker, J. M. Chapman, G. Gyenes, B. Vali, M. D. Hyrcza, F. Y. Yue, C. Kovacs, A. Sassi, M. Loutfy, R. Halpenny, D. Persad, G. Spotts, F. M. Hecht, T.-W. Chun, J. M. McCune, R. Kaul, J. M. Rini, D. F. Nixon, M. A. Ostrowski, Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205, 2763-2779 (2008).
12. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
13. + lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLOS Pathog. 6, e1000747 (2010).
14. + T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells. PLOS Pathog. 6, e1000748 (2010).
15. G. Pantaleo, J. F. Demarest, T. Schacker, M. Vaccarezza, O. J. Cohen, M. Daucher, C. Graziosi, S. S. Schnittman, T. C. Quinn, G. M. Shaw, L. Perrin, G. Tambussi, A. Lazzarin, R. P. Sekaly, H. Soudeyns, L. Corey, A. S. Fauci, The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc. Natl. Acad. Sci. U.S.A. 94, 254-258 (1997).
16. G. S. Arnoczy, G. Ferrari, N. Goonetilleke, T. Corrah, H. Li, J. Kuruc, J. L. Schmitz, K. McGee, C. Hicks, J. J. Eron; Center for HIV/AIDS Vaccine Immunology AI067854, Massive CD8 T cell response to primary HIV infection in the setting of severe clinical presentation. AIDS Res. Hum. Retroviruses 28, 789-792 (2012).
17. L. Trautmann, F.-M. Mbitikon-Kobo, J.-P. Goulet, Y. Peretz, Y. Shi, J. Van Grevenynghe, F. A. Procopio, M. R. Boulassel, J.-P. Routy, N. Chomont, E. K. Haddad, R.-P. Sekaly, Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood 120, 3466-3477 (2012).
18. + T cell activation during Hyperacute HIV infection impact viral set point. Immunity 43, 591-604 (2015).
19. S. G. Deeks, HIV: Shock and kill. Nature 487, 439-440 (2012).
20. B. Autran, Toward a cure for HIV-Seeking effective therapeutic vaccine strategies. Eur. J. Immunol. 45, 3215-3221 (2015).
21. G. H. Mylvaganam, G. Silvestri, R. R. Amara, HIV therapeutic vaccines: Moving towards a functional cure. Curr. Opin. Immunol. 35, 1-8 (2015).
22. S. G. Hansen, J. C. Ford, M. S. Lewis, A. B. Ventura, C. M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, A. W. Legasse, M. J. Chiuchiolo, C. L. Parks, M. K. Axthelm, J. A. Nelson, M. A. Jarvis, M. Piatak Jr., J. D. Lifson, L. J. Picker, Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
23. S. G. Hansen, M. Piatak Jr., A. B. Ventura, C. M. Hughes, R. M. Gilbride, J. C. Ford, K. Oswald, R. Shoemaker, Y. Li, M. S. Lewis, A. N. Gilliam, G. Xu, N. Whizin, B. J. Burwitz, S. L. Planer, J. M. Turner, A. W. Legasse, M. K. Axthelm, J. A. Nelson, K. Früh, J. B. Sacha, J. D. Estes, B. F. Keele, P. T. Edlefsen, J. D. Lifson, L. J. Picker, Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
24. + T cell epitope recognition paradigms. Science 340, 1237874 (2013).
25. + T cell responses restricted by major histocompatibility complex E. Science 351, 714-720 (2016).
26. + T cell efficacy in vaccination and disease. Nat. Med. 14, 623-628 (2008).
27. + T cells and HIV eradication. J. Clin. Invest. 126, 455-463 (2016).
28. L. Trautmann, Kill: Boosting HIV-specific immune responses. Curr. Opin. HIV AIDS 11, 409-416 (2016).
29. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162, 1780-1788 (1999).
30. S. A. Kalams, P. J. Goulder, A. K. Shea, N. G. Jones, A. K. Trocha, G. S. Ogg, B. D. Walker, Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73, 6721-6728 (1999).
31. G. S. Ogg, X. Jin, S. Bonhoeffer, P. Moss, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, A. Hurley, M. Markowitz, D. D. Ho, A. J. McMichael, D. F. Nixon, Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797-800 (1999).
32. + T cells in peripheral blood after initiation of highly active antiretroviral therapy. J. Virol. 75, 6508-6516 (2001).
33. + T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J. Virol. 83, 11876-11889 (2009).
34. L. Janbazian, D. A. Price, G. Canderan, A. Filali-Mouhim, T. E. Asher, D. R. Ambrozak, P. Scheinberg, M. R. Boulassel, J.-P. Routy, R. A. Koup, D. C. Douek, R.-P. Sekaly, L. Trautmann, Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation. J. Immunol. 188, 1156-1167 (2012).
35. + T cells: Implications for the development of therapeutic strategies. Proc. Natl. Acad. Sci. U.S A. 98, 253-258 (2001).
36. L. Shan, K. Deng, N. S. Shroff, C. M. Durand, S. A. Rabi, H. C. Yang, H. Zhang, J. B. Margolick, J. N. Blankson, R. F. Siliciano, Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501 (2012).
37. K. Deng, M. Pertea, A. Rongvaux, L. Wang, C. M. Durand, G. Ghiaur, J. Lai, H. L. McHugh, H. Hao, H. Zhang, J. B. Margolick, C. Gurer, A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, S. G. Deeks, T. Strowig, P. Kumar, J. D. Siliciano, S. L. Salzberg, R. A. Flavell, L. Shan, R. F. Siliciano, Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381-385 (2015).
38. J. Ananworanich, A. Schuetz, C. Vandergeeten, I. Sereti, M. de Souza, R. Rerknimitr, R. Dewar, M. Marovich, F. van Griensven, R. Sekaly, S. Pinyakorn, N. Phanuphak, R. Trichavaroj, W. Rutvisuttinunt, N. Chomchey, R. Paris, S. Peel, V. Valcour, F. Maldarelli, N. Chomont, N. Michael, P. Phanuphak, J. H. Kim; RV254/SEARCH 010 Study Group, Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLOS ONE 7, e33948 (2012).
39. J. Ananworanich, C. P. Sacdalan, S. Pinyakorn, N. Chomont, M. de Souza, T. Luekasemsuk, A. Schuetz, S. J. Krebs, R. Dewar, L. Jagodzinski, S. Ubolyam, R. Trichavaroj, S. Tovanabutra, S. Spudich, V. Valcour, I. Sereti, N. Michael, M. Robb, P. Phanuphak, J. H. Kim, N. Phanuphak, Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. J Virus Erad 2, 43-48 (2016).
40. M. L. Robb, L. A. Eller, H. Kibuuka, K. Rono, L. Maganga, S. Nitayaphan, E. Kroon, F. K. Sawe, S. Sinei, S. Sriplienchan, L. L. Jagodzinski, J. Malia, M. Manak, M. S. de Souza, S. Tovanabutra, E. Sanders-Buell, M. Rolland, J. Dorsey-Spitz, M. A. Eller, M. Milazzo, Q. Li, A. Lewandowski, H. Wu, E. Swann, R. J. O'Connell, S. Peel, P. Dawson, J. H. Kim, N. L. Michael; RV 217 Study Team, Prospective study of acute HIV-1 infection in adults in East Africa and Thailand. N. Engl. J. Med. 374, 2120-2130 (2016).
41. th generation immunoassay. Retrovirology 10, 56 (2013).
42. K. Murali-Krishna, J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, R. Ahmed, Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection. Immunity 8, 177-187 (1998).
43. + T cell responses to smallpox and yellow fever vaccines. Immunity 28, 710-722 (2008).
44. L. Papagno, C. A. Spina, A. Marchant, M. Salio, N. Rufer, S. Little, T. Dong, G. Chesney, A. Waters, P. Easterbrook, P. R. Dunbar, D. Shepherd, V. Cerundolo, V. Emery, P. Griffiths, C. Conlon, A. J. McMichael, D. D. Richman, S. L. Rowland-Jones, V. Appay, Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLOS Biol. 2, E20 (2004).
45. + T cell function by the transcription factor Eomesodermin. Science 302, 1041-1043 (2003).
46. B. M. Sullivan, A. Juedes, S. J. Szabo, M. von Herrath, L. H. Glimcher, Antigen-driven effector CD8 T cell function regulated by T-bet. Proc. Natl. Acad. Sci. U.S.A. 100, 15818-15823 (2003).
47. + T cell response. J. Immunol. 183, 7919-7930 (2009).
48. + T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: Too late and too little. J. Virol. 79, 9228-9235 (2005).
49. Q. Li, P. J. Skinner, S.-J. Ha, L. Duan, T. L. Mattila, A. Hage, C. White, D. L. Barber, L. O'Mara, P. J. Southern, C. S. Reilly, J. V. Carlis, C. J. Miller, R. Ahmed, A. T. Haase, Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 323, 1726-1729 (2009).
50. A. R. Stacey, P. J. Norris, L. Qin, E. A. Haygreen, E. Taylor, J. Heitman, M. Lebedeva, A. DeCamp, D. Li, D. Grove, S. G. Self, P. Borrow, Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719-3733 (2009).
51. S. Eriksson, E. H. Graf, V. Dahl, M. C. Strain, S. A. Yukl, E. S. Lysenko, R. J. Bosch, J. Lai, S. Chioma, F. Emad, M. Abdel-Mohsen, R. Hoh, F. Hecht, P. Hunt, M. Somsouk, J. Wong, R. Johnston, R. F. Siliciano, D. D. Richman, U. O'Doherty, S. Palmer, S. G. Deeks, J. D. Siliciano, Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLOS Pathog. 9, e1003174 (2013).
52. + T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 97, 3382-3387 (2000).
53. M. Altfeld, E. S. Rosenberg, R. Shankarappa, J. S. Mukherjee, F. M. Hecht, R. L. Eldridge, M. M. Addo, S. H. Poon, M. N. Phillips, G. K. Robbins, P. E. Sax, S. Boswell, J. O. Kahn, C. Brander, P. J. R. Goulder, J. A. Levy, J. I. Mullins, B. D. Walker, Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193, 169-180 (2001).
54. F. M. Hecht, L. Wang, A. Collier, S. Little, M. Markowitz, J. Margolick, J. M. Kilby, E. Daar, B. Conway, S. Holte; AIEDRP Network, A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J. Infect. Dis. 194, 725-733 (2006).
55. C. Cellerai, A. Harari, H. Stauss, S. Yerly, A.-M. Geretti, A. Carroll, T. Yee, J. Ainsworth, I. Williams, J. Sweeney, A. Freedman, M. Johnson, G. Pantaleo, S. K.-d. Loes, Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-Cell profile comparable to that of long-term non-progressors. PLOS ONE 6, e18164 (2011).
56. P. Paci, F. Martini, M. Bernaschi, G. D'Offizi, F. Castiglione, Timely HAART initiation may pave the way for a better viral control. BMC Infect. Dis. 11, 56 (2011).
57. J. D. Altman, P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, M. M. Davis, Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
58. S. L. Spurgeon, R. C. Jones, R. Ramakrishnan, High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLOS ONE 3, e1662 (2008).
59. C. Vandergeeten, R. Fromentin, E. Merlini, M. B. Lawani, S. DaFonseca, W. Bakeman, A. McNulty, M. Ramgopal, N. Michael, J. H. Kim, J. Ananworanich, N. Chomont, Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J. Virol. 88, 12385-12396 (2014).